Qlucore AB

QCORE

SE0016829824

Software

Market Closed - Nasdaq Stockholm Other stock markets 07:22:49 2024-04-24 am EDT			5-day change	1st Jan Change
8.15 ^SEK	-2.98%		+0.62%	+6.54%

Apr. 08	Qlucore Announces the Launch of the Qlucore Omics Explorer Cloud Version	CI
Feb. 28	Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI

Invitation to presentation including Q&A session of Qlucore’s interim report for the period, 1 May – 31 July 2022

August 25, 2022 at 04:31 am EDT

Qlucore’s interim report for the period 1 May to 31 July 2022 will be published 30 August 2022.

Qlucore invites to a video and phone conference where the interim report for the period, 1 May – 31 July 2022, will be presented by the CEO. After the presentationen there will be a Q&A session.
The presentation will be in Swedish. Questions can be asked in English.
Date: Wednesday 31 August at 10 am CET.

Meeting link: https://qlucore.webex.com/qlucore/j.php?MTID=m8593629b2db9c9e6e2465ddde51240ef

Meeting number (access code): 2730 957 8916
Password: mSWhp2BTG32
Join per phone
+46 85051 3563 Sweden toll

About Qlucore

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a Do-It-Yourself bioinformatics software for research in the life science, plant- and biotech industries, as well as academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com

Latest news about Qlucore AB

Qlucore Announces the Launch of the Qlucore Omics Explorer Cloud Version	Apr. 08	CI
Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Feb. 28	CI
Qlucore AB Announces Grant from EU	Feb. 27	CI
Qlucore Submits Technical Documentation for CE Marking of Pediatric Leukemia Medical Device	Jan. 30	MT
Qlucore Diagnostics for Pediatric Leukemia Takes A Significant Step Closer to Ce Marking	Jan. 30	CI
Sahlgrenska Hospital Invests in Precision Diagnostics with Qlucore AB Insights	Jan. 16	CI
Boehringer Ingelheim Signs Two-Year Agreement with Qlucore	Jan. 11	CI
Qlucore Announces Swedish Innovation Evaluated for Clinical Diagnosis of Pediatric Leukemia	Dec. 13	CI
Qlucore AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Nov. 28	CI
Qlucore AB Appoints Lars Höckenström as A Member of the Board of Directors	23-09-07	CI
Qlucore AB Reports Earnings Results for the First Quarter Ended July 31, 2023	23-08-30	CI
Qlucore AB Reports Earnings Results for the Fourth Quarter Ended April 30, 2023	23-05-31	CI
Qlucore AB Reports Earnings Results for the Full Year Ended April 30, 2023	23-05-31	CI
Qlucore Launches Qlucore Omics Explorer Version 3.9	23-04-26	CI
Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-02-28	CI
Qlucore AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-11-28	CI
Qlucore Software Used in New Project to Prevent Cardiovascular Diseases	22-11-17	CI
Qlucore Receives Patent in Europe	22-09-26	CI
Qlucore Ab Reports Earnings Results for the First Quarter Ended July 31, 2022	22-08-30	CI
Qlucore to Develop Diagnostics Product for Two Blood Cancer Types	22-08-26	MT
Qlucore Expands Its Leukemia Diagnostics Solution	22-08-26	CI
Certain Shares of Qlucore AB are subject to a Lock-Up Agreement Ending on 5-AUG-2022.	22-08-04	CI
Qlucore Ab Reports Earnings Results for the Full Year Ended April 30, 2022	22-06-08	CI
Qlucore Announces New Collaboration in the Field of Precision Diagnostics to Develop Solutions for Improved Clinical Diagnostics of Bladder Cancer	22-05-23	CI
Qlucore Names Erik Söderbäck as Head of Diagnostics Sales	22-04-07	CI

Chart Qlucore AB

Duration

Period

More charts

Company Profile

Qlucore AB is a Sweden-based provider of new generation of intuitive bioinformatics software for research and precision and companion diagnostics. Its mission is to make it easier to analyze the vast amounts of complex data generated by innovations in genomics and proteomics. This is done by providing visualization-based analysis data tools for bioinformatics for research and precision diagnostics. The tools are so easy to use that researchers, technicians and doctors can easily interpret and explore their data sets. Qlucore Diagnostics software is a platform for multi-omics companion and precision diagnostics. AI-driven, disease-specific machine learning-based classification models are combined with patient-friendly visualizations in an easy-to-use and cost-effective software solution that integrates with a wide range of data-generating technologies and instruments. Qlucore was founded in 2007 by researchers at the departments of mathematics and clinical genetics at Lund University.

Sector

Software

Calendar

2024-05-30 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Software

	1st Jan change	Capi.
QLUCORE AB	+6.54%	3.01M
MICROSOFT CORPORATION	+8.78%	3,039B
SYNOPSYS INC.	+2.45%	80.47B
CADENCE DESIGN SYSTEMS, INC.	+1.94%	75.69B
DASSAULT SYSTÈMES SE	-11.97%	54.73B
ATLASSIAN CORPORATION	-16.33%	51.62B
PALANTIR TECHNOLOGIES INC.	+25.74%	47.77B
THE TRADE DESK, INC.	+16.44%	40.95B
SEA LIMITED	+56.22%	35.86B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-11.26%	24.36B